Who
David W. Gryska
Director
Company insider
Files Form 4 as: Director, Celcuity; Director, Forte Biosciences; Director, Definium Therapeutics; Director, Seagen; Director, Aerie Pharmaceuticals; Director, Gw Pharmaceuticals; Director, Pdl Biopharma; Executive Vice President, CFO, Incyte.
In numbers
- Trades disclosed
- 289
- Buys
- 2
- Sells
- 32
- Bought
- $39K
- Sold
- $23.7M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 14 Feb 2006
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | CELC CelcuityBiotechnology | SEC FORM 4 Code A | —893 at $0.00 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte BiosciencesBiotechnology | SEC FORM 4 Code U | —5,940 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,000 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,353 | filing |
| 27 Aug 2026filed 27 Aug 2026 | Forte BiosciencesBiotechnology | SEC FORM 4 Code U | —5,940 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,666 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,188 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,188 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,666 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,353 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,353 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,187 at $0.00 | filing |
News
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 7.5% – Time to Buy?DFTX · dailypolitical.com · 9 Oct 2026
0 headlines in the last 90 days name David W. Gryska; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.